Skip to content

A clinical study on expanding donor pool and improving recipients' life quality and long-term survival: Bone marrow cells infusion modulating immune reaction, inducing tolerance, and improving long-term survival

A clinical study on expanding donor pool and improving recipients' life quality and long-term survival: Bone marrow cells infusion modulating immune reaction, inducing tolerance, and improving long-term survival

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003199
Enrollment
Unknown
Registered
2013-04-26
Start date
2013-05-01
Completion date
Unknown
Last updated
2021-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Organ Transplantation

Interventions

Bone Marrow cells infusion:donor bone marrow cells infusion
donor bone fragment:donor bone fragment
Bone Marrow cells infusion + donor bone fragment i:Bone Marrow cells infusion + donor bone fragment

Sponsors

Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1, agree to participate in this study and give informed consent;2, age 18-65 years old, both male and female;3, the first time to receive a kidney transplant.

Exclusion criteria

Exclusion criteria: 1. the warm ischemic time>10min; 2. the cold ischemic time>24hours; 3. fail to complete the related examinations; 4. donor and recipient with HBV,HCV,and AIDS; 5. participating any other clinical trial; have been participated any other clinical trial during the past 12 weeks; 6. other situations that should be excluded into this study.

Design outcomes

Primary

MeasureTime frame
serum creatinine;GFR;DGF;rejection diagnosed by clinical data;rejection diagnosed by pathology;infection complications;kidney allograft pathology;bone fragments detection;

Secondary

MeasureTime frame
urine rountine;other complications;ELISPOT;Immuno-Cylex;chimera detection;immunosuppresive regimen;CNI/Rapa concentration;MPA trough level/AUC;HLA matching;complement-dependent cytotoxicity;panel reaction antibody;

Countries

China

Contacts

Public ContactChen Xiaoping
qgyzlc@tjh.tjmu.edu.cn+86 027 83665283

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026